Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.55 |
| ▸ | MET | P08581 | 12/20 | 0.55 |
| ▸ | MST1R | Q04912 | 7/20 | 0.55 |
| ▸ | AXL | P30530 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | HCK | P08631 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | ABL2 | P42684 | 1/20 | 0.45 |
| ▸ | FRK | P42685 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15074671 | 0.92 | KDR (0.56) | KDRMETMST1RAXLFLT3 | |
| SCHEMBL2671060 | 0.86 | MET (0.52) | KDRMETMST1RAXLFLT3 | |
| SCHEMBL2670651 | 0.85 | MET (0.50) | KDRMETMST1RAXLFLT3 | |
| SCHEMBL14747724 | 0.84 | MET (0.50) | KDRMETMST1RAXLFLT3 | |
| SCHEMBL10202683 | 0.82 | MET (0.48) | KDRMETMST1RAXLFLT3 | |
| SCHEMBL13667868 | 0.82 | KDR (0.44) | KDRMETMST1RAXLFLT3 | |
| SCHEMBL1479192 | 0.81 | MET (0.52) | KDRMETMST1RAXLFLT3 | |
| SCHEMBL2670491 | 0.81 | MET (0.62) | KDRMETMST1RAXLFLT3 | |
| SCHEMBL2670911 | 0.81 | MET (0.70) | KDRMETMST1RAXLFLT3 | |
| SCHEMBL2670881 | 0.81 | MET (0.47) | KDRMETMST1RAXLFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183254-B1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2017-06-21 | — | — | EP | disclosed |
| EP-2183254-B1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2017-06-21 | — | — | EP | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| WO-2009026717-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | KDR 11/4885MET 3/4885MST1R 104/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | KDR 11/4885MET 3/4885MST1R 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.